SR-B1-targeted nanodelivery of anti-cancer agents: a promising new approach to treat triple-negative breast cancer

References

• World Health OrganizationStewartBWildCWorld Cancer Report 20142014 Available from https://www.iarc.fr/en/media-centre/pr/2014/pdfs/pr224_E.pdfAccessed December 12, 2014
   Google Scholar
• MilesDRecent advances in systemic therapy. When HER2 is not the target: advances in treatment of HER2-negative metastatic breast cancerBreast Cancer Res200911420819744307
   PubMed Web of Science ®Google Scholar
• RakhaEAReis-FilhoJSEllisIOBasal-like breast cancer: a critical reviewJ Clin Oncol200826152568258118487574
   PubMed Web of Science ®Google Scholar
• CleatorSHellerWCoombesRCTriple-negative breast cancer: therapeutic optionsLancet Oncol20078323524417329194
   PubMed Web of Science ®Google Scholar
• LiedtkeCMazouniCHessKRResponse to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancerJ Clin Oncol20082681275128118250347
   PubMed Web of Science ®Google Scholar
• BosPDZhangXHNadalCGenes that mediate breast cancer metastasis to the brainNature200945972491005100919421193
   PubMed Web of Science ®Google Scholar
• HudisCAGianniLTriple-negative breast cancer: an unmet medical needOncologist201116suppl 1111
   PubMed Web of Science ®Google Scholar
• ManciniPAngeloniARisiEOrsiCMeziSStandard of care and promising new agents for triple negative metastatic breast cancerCancers (Basel)201464187223
   Web of Science ®Google Scholar
• LehmannBDBauerJAChenXIdentification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJ Clin Invest201112172750276721633166
   PubMed Web of Science ®Google Scholar
• SchettiniFGiulianoMDe PlacidoSArpinoGNab-paclitaxel for the treatment of triple-negative breast cancer: rationale, clinical data and future perspectivesCancer Treat Rev20165012914127665540
   PubMed Web of Science ®Google Scholar
• HagiwaraHSunadaYMechanism of taxane neurotoxicityBreast Cancer2004111828514718798
   PubMedGoogle Scholar
• ZhangJFLiuJWangYZhangBNovel therapeutic strategies for patients with triple-negative breast cancerOnco Targets Ther201696519652827799799
   PubMed Web of Science ®Google Scholar
• LeeESNaKBaeYHDoxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumorJ Control Release2005103240541815763623
   PubMed Web of Science ®Google Scholar
• PatelNRRathiAMongaytDTorchilinVPReversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomesInt J Pharm2011416129629921703341
   PubMed Web of Science ®Google Scholar
• JohnsonRSabnisNMcConathyWJLackoAGThe potential role of nanotechnology in therapeutic approaches for triple negative breast cancerPharmaceutics20135235337024244833
   PubMedGoogle Scholar
• GuoYHeWYangSZhaoDLiZLuanYCo-delivery of docetaxel and verapamil by reduction-sensitive PEG-PLGA-SS-DTX conjugate micelles to reverse the multi-drug resistance of breast cancerColloids Surf B Biointerfaces201715111912727988472
   PubMed Web of Science ®Google Scholar
• ZhangYLeonardMShuYOvercoming tamoxifen resistance of human breast cancer by targeted gene silencing using multifunctional prank nanoparticlesACS Nano201711133534627966906
   PubMed Web of Science ®Google Scholar
• LackoANairMParanjapeSMooberryLMcConathyWTrojan horse meets magic bullet to spawn a novel, highly effective drug delivery modelChemotherapy200652417117316691026
   PubMed Web of Science ®Google Scholar
• McConathyWJNairMParanjapeSMooberryLLackoAGEvaluation of synthetic/reconstituted high density lipoproteins (rHDL) as delivery vehicles for paclitaxelAnticancer Drugs200819218318818176115
   PubMed Web of Science ®Google Scholar
• SabnisNANairMIsraelMMcConathyWJLackoAGEnhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticlesInt J Nanomedicine2012797598322393294
   PubMed Web of Science ®Google Scholar
• SabnisNPratapSAkopovaIBowmanWPLackoAGPre-clinical evaluation of rHDL encapsulated retinoid for the treatment of neuroblastomaFront Pediatr Oncol20131110
   Web of Science ®Google Scholar
• ShahzadMMMangalaLSHanHDTargeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticlesNeoplasia201113430931921472135
   PubMed Web of Science ®Google Scholar
• KuaiRLiDChenYEMoonJJSchwendemanAHigh-density lipo-proteins: nature’s multifunctional nanoparticlesACS Nano20161033015304126889958
   PubMed Web of Science ®Google Scholar
• CruzPMMoHMcConathyWJSabnisNLackoAGThe role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeuticsFront Pharmacol201341723346057
   PubMed Web of Science ®Google Scholar
• GospodarowiczDLuiGMGonzalezRHigh-density lipoproteins and the proliferation of human tumor cells maintained on extracellular matrix-coated dishes and exposed to defined mediumCancer Res1982429370437137049362
   PubMed Web of Science ®Google Scholar
• DaniloCGuiterrez-PajaresJMaineriMScavenger receptor class B type 1 regulates cellular cholesterol metabolism and cell signaling associated with breast cancer developmentBreast Cancer Res2013155R8724060386
   PubMed Web of Science ®Google Scholar
• WadsackCHirschmuglBHammerAScavenger receptor class B, type I on non-malignant and malignant human epithelial cells mediates cholesteryl ester-uptake from high density lipoproteinsInt J Biochem Cell Biol200335444145412565706
   PubMed Web of Science ®Google Scholar
• LackoAGNairMParanjapeSJohnsonSMcConathyWJHigh density lipoprotein complexes as delivery vehicles for anticancer drugsAnticancer Res20022242045204912174882
   PubMed Web of Science ®Google Scholar
• YuanBWuCWangXHigh scavenger receptor class B type 1 expression is related to tumor aggressiveness and poor prognosis in breast cancerTumor Biol201537318
   Google Scholar
• MooberryLKNairMParanjapeSMcConathyWJLackoAGReceptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrierJ Drug Target2010181535819637935
   PubMed Web of Science ®Google Scholar
• JiangWKimBRutkaJChanWNanoparticle-mediated cellular response is size dependentNat Nanotechnol20083314515018654486
   PubMed Web of Science ®Google Scholar
• National Cancer Institute [webpage on the Internet]SEER Fact Sheet: Female Breast Cancer2013 Available from: www.seer.cancer.gov/statfacts/html/breast.htmlAccessed April 3, 2016
   Google Scholar
• DietzeECSistrunkCMiranda-CarboniGO’ReganRSeewaldtVLTriple-negative breast cancer in African-American women: disparities versus biologyNat Rev Cancer201515424825425673085
   PubMed Web of Science ®Google Scholar
• WabhaHAEl-HadaadHACurrent approaches in treatment of triple-negative breast cancerCancer Biol Med201512210611626175926
   PubMed Web of Science ®Google Scholar
• RobinsonPKasembeliMBharadwajUEngineerNEckolsKTTweardyDJSubstance P receptor signaling mediates doxorubicin-induced cardiomyocyte apoptosis and triple-negative breast cancer chemoresistanceBiomed Res Int20162016195927026981525
   PubMed Web of Science ®Google Scholar
• AndersCKAbramsonVTanTDentRThe evolution of triple-negative breast cancer: from biology to novel therapeuticsAm Soc Clin Oncol Educ Book201635344227249684
   PubMedGoogle Scholar
• ZhangZCaoWJinHBiomimetic nanocarrier for direct cytosolic drug deliveryAngew Chem Int Ed Engl200948489171917519876988
   PubMed Web of Science ®Google Scholar